Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, July 2002, p. 2269-2272, Vol. 46, No. 7
0066-4804/02/$04.00+0 DOI: 10.1128/AAC.46.7.2269-2272.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.
Fluorescence Assay for Studying the Ability of Macrolides To Induce Production of Ribosomal Methylase
Gervais Clarebout and Roland Leclercq*
Service de Microbiologie, UPRES EA 2128, Hôpital Côte de Nacre, Université de Caen, 14033 Caen Cedex, France
Received 27 September 2001/
Returned for modification 5 January 2002/
Accepted 7 April 2002

ABSTRACT
A screening assay to test the inducing capacity of macrolides
by fusing the attenuator of the inducible
erm(B) gene from
Streptococcus pneumoniae HM28 with the
gfpmut1 gene has been designed. Fluorescence
was detected under UV light around disks impregnated with inducer
macrolides (erythromycin or azithromycin) but not with noninducer
ketolides. Induction could be quantified by fluorometry.

TEXT
Resistance to macrolide-lincosamide-streptogramin B antibiotics
defining the so-called MLS phenotype is common in streptococci
and enterococci (
11). It is mediated by dimethylation of adenine
2058 in the ribosomal 23S rRNA target, which reduces the affinity
between the antibiotic and the ribosome (
17). The genes that
encode 23S rRNA methylases are designated
erm (erythromycin
resistance methylase). In streptococci and enterococci, MLS
resistance is generally encoded by genes belonging to the
erm(B)
group (
13). Expression of MLS resistance may be inducible or
constitutive, depending upon a regulatory region preceding the
gene (
10,
18). In contrast to the pattern of inducer macrolides
for the staphylococcal gene
erm(C), which is limited to 14-
and 15-member ring macrolides,
erm(B) is inducible by most members
of the MLS group (
10). Recently, a new class of macrolides,
the ketolides, which are derivatives of clarithromycin or erythromycin
A characterized by a 3-keto function instead of the cladinose
moiety and an 11- or 12-carbamate extension, has been shown
to be active against most streptococci resistant to erythromycin
(
1,
3,
7,
8; C. Agouridas, Y. Benedetti, A. Denis, O. Le Martret,
and J. F. Chantot, Abstr. 35th Intersci. Conf. Antimicrob. Agents
Chemother., abstr. F157, 1995). This activity was attributed,
in part, to the lack of induction of MLS resistance by these
antimicrobials (
2,
3,
5,
19). We have fused the inducible attenuator
of
erm(B) with the green fluorescent protein reporter gene to
provide a new fluorescence assay to easily detect the inducing
capacity of macrolides and related antimicrobials.
Gene fusions.
We have amplified by PCR a 741-bp fragment from plasmid pAT505 composed of the entire gfpmut1 gene except the initiation codon (9) using oligonucleotides modified by insertion of SmaI and PstI restriction sites (underlined): GFP1 (5'-GGA GAT ATC CCC GGG GGT AAA GGA GAA G-3') and GFP2 (5'-GCA TGC CTG CAGTTA TTT GTA CAA TT-3'). The PCR product was digested with SmaI and PstI, cloned in pUC18, and introduced into Escherichia coli DH10B cells by electrotransformation. A 384-bp fragment comprising the attenuator and the first 54 nucleotides of the erm(B) gene of Streptococcus pneumoniae HM28 inducibly resistant to MLS antibiotics (14) was amplified by PCR using oligonucleotides modified to include restriction sites EcoRI and SmaI (underlined): ermB1 (5'-CTT AGA AGA ATT C TT AAG AGT GTG-3') and ermB2 (5'-TTA TTA TTT GCC CGG GTA CCT TTT C-3'). The amplification product was digested with the appropriate enzymes and cloned upstream from the truncated gfpmut1 gene in pUC18. The fusion was electrotransformed into E. coli DH10B and subcloned in the EcoRI and SphI restriction sites of the shuttle multicopy vector pAT28 (which confers spectinomycin resistance) (16) to generate plasmid pUV4. The hybrid plasmids were introduced by electrotransformation into Staphylococcus aureus RN4220. The transformants were plated onto media containing 180 µg of spectinomycin/ml and an inducing concentration of erythromycin (0.03 µg/ml). The fluorescent colonies were identified by UV (at 385 nm).
A constitutively expressed gfpmut1 gene was also constructed by fusion of the gfpmut1 gene with a 179-bp sequence upstream from the constitutive erm(B) gene of Enterococcus faecalis BM4110/pAMß1 amplified by PCR with the ermB1 and ermB2 primers. The amplified fragment lacked the leader peptide sequence (12). The recombinant plasmid, pUV5, was electrotransformed into S. aureus RN4220 and used as a positive control.
MICs and induction experiments.
MICs of antibiotics were determined by agar dilution using Mueller-Hinton medium (Bio-Rad, Marnes-la-Coquette, France) supplemented with 5% horse blood (4). The following antibiotics were provided by their manufacturers: telithromycin, RU 69874, and the 2-fluoroketolides HMR 3562 and HMR 3787 (Aventis, Romainville, France) (6). RU 69874 is structurally similar to telithromycin except for a replacement of the 3-keto function by a L-cladinose sugar. Erythromycin, spectinomycin, and amoxicillin were from Sigma-Aldrich (St. Quentin Fallavier, France), and azithromycin was from Pfizer (Orsay, France). Induction of resistance by antibiotics was further assessed by growth curves of uninduced or induced cells (at a concentration equal to 1/10 the MIC of the macrolides) in the presence or absence of challenging (just subinhibitory) concentrations of antibiotic as described earlier (15). Bacterial growth was followed by CO2 production measured with the BacT/Alert 3D system (Organon Teknika Corp., Oklahoma City, Okla.). Growth curves were plotted and lag phases were calculated. All experiments were conducted twice.
Fluorescence induction assays.
Fluorescence induction was detected qualitatively by the disk diffusion method (4). Disks impregnated with 15 µg of the various macrolides and ketolides were placed on inoculated blood agar plates which were incubated for 24 h at 37°C and observed under UV light. For quantitative assays, overnight S. aureus RN4220/pUV4 or S. aureus RN4220/pUV5 cultures grown in Trypticase soy broth were used to inoculate fresh medium at a dilution of 1: 25. After 3 h of incubation at 37°C under aeration, cells were added to Trypticase soy broth at 106 CFU/ml, containing increasing concentrations of antibiotics, and incubated for 1 h at 37°C. The cultures were then washed three times with phosphate-buffered saline, and cells were resuspended in phosphate-buffered saline at 106 CFU/ml. The fluorescence intensity was determined by spectrofluorometry performed with a Hitachi model F-1200 fluorescence spectrophotometer (Hitachi Co., Tokyo, Japan) at an excitation wavelength of 460 nm and an emission wavelength of 510 nm.
MLS resistance phenotypes.
The MICs of and induction of resistance by erythromycin, telithromycin, and RU 69874 were determined for S. pneumoniae HM28 and E. faecalis BM4110/pAMß1 (Table 1). Preinduced cells of S. pneumoniae HM28 challenged with erythromycin had a lag phase that was shortened, confirming that MLS resistance was inducible by this antimicrobial. As expected, expression of erythromycin resistance in E. faecalis BM4110/pAMß1 was constitutive. Telithromycin did not appear to be an inducer for MLS resistance in S. pneumoniae HM28; in contrast, RU 69874 did reduce the lag phase, confirming the role of the L-cladinose residue in induction. Telithromycin was active only against the inducible strain S. pneumoniae HM28.
View this table:
[in this window]
[in a new window]
|
TABLE 1. Induction of MLS resistance assessed by growth curve measurements against strains used in fusion experimentsc
|
Induction of fluorescence by macrolides.
The ability of erythromycin and ketolides to induce fluorescence
was studied with fusion constructs. After exposure to UV light,
agar plates spread with
S. aureus RN4220/pUV4 exhibited fluorescence
localized at the border of inhibition zones for disks containing
erythromycin and spiramycin. Fluorescence was barely visible
with telithromycin and HMR 3787; however, HMR 3562 induced a
weak fluorescence (Fig.
1). Fluorescence was strongly expressed
in the presence of RU 69874. The fluorescence of
S. aureus RN4220/pUV5
was expressed in the absence of antibiotic and was not enhanced
in the presence of erythromycin or spiramycin (data not shown).
Fluorescence expressed in the presence of erythromycin, azithromycin,
telithromycin, RU 69874, and two fluoroketolides (HMR 3562 and
HMR 3787) was quantified by spectrofluorometry (Fig.
2). For
noninduced
S. aureus RN4220/pUV4, no basal fluorescence could
be detected, while cells of
S. aureus RN4220/pUV5 expressed
a fluorescence equal to approximately 90 U, irrespective of
the presence or absence of a macrolide (data not shown). Azithromycin
and erythromycin were strong inducers with fluorescence peaks
reaching 194 U at 0.09 µg/ml and 144 U at 0.06 µg/ml,
respectively. Fluorescence was detected at 0.02 to 0.1 times
the MIC of the macrolides for
S. aureus RN4220/pUV4, reaching
a peak at nearly one-quarter to one-half the MIC and then decreasing
rapidly at higher concentrations. By contrast, telithromycin
(Fig.
2) and the 2-fluoroketolides HMR 3562 and HMR 3787 (data
not shown) induced a very weak fluorescence. The fluorescence
maxima were 14.6, 18.6, and 21.4 U for telithromycin, HMR 3562,
and HMR 3787, respectively. As expected, RU 69874 induced marked
fluorescence.
Therefore, the pattern of induction by the antibiotics was similar,
as determined by fluorescence or growth curve experiments. However,
the fluorescence assay was convenient and easy to use, since
it did not require substrates or cofactors. Additionally, the
reporter system also delineates viable cells (A. Lefort, M.
Arthur, C. Vignes-Colombeix, C. Vissuzaine, D. Henin, C. Carbon,
and P. Courvalin, Abstr. 40th Intersci. Conf. Antimicrob. Agents
Chemother., abstr. 668, 2000). This assay can be used to study
qualitatively or quantitatively the relationship between structure
and activity of the macrolides, ketolides, or any inducer of
methylase production.

ACKNOWLEDGMENTS
We thank Patrice Courvalin and Stanley Falkow for the gift of
plasmid pAT505 containing
gfpmut1.
This work was supported by grants from Aventis and the Fondation de la Recherche Médicale.

FOOTNOTES
* Corresponding author. Mailing address: CHU de Caen, Service de Microbiologie, Avenue Côte de Nacre, 14033 Caen Cedex, France. Phone: (33) 02 31 06 45 72. Fax: (33) 02 31 06 45 73. E-mail:
leclercq-r{at}chu-caen.fr.


REFERENCES
1
- Agouridas, C., A. Bonnefoy, and J. F. Chantot. 1997. Antibacterial activity of RU64004 (HMR 3004), a novel ketolide derivative active against respiratory pathogens. Antimicrob. Agents Chemother. 41:2149-2158.[Abstract]
2
- Bonnefoy, A., A. M Girard, C. Agouridas, and J. F. Chantot. 1997. Ketolides lack inducibility properties of MLS(B) resistance phenotype. J. Antimicrob. Chemother. 40:85-90.[Abstract/Free Full Text]
3
- Bryskier, A. 2000. Ketolidestelithromycin, an example of a new class of antibacterial agents. Clin. Microbiol. Infect. 6:661-669.[CrossRef][Medline]
4
- Comité de l'Antibiogramme de la Société Française de Microbiologie. 1996. Technical recommendations for in vitro susceptibility testing. Clin. Microbiol. Infect. 2(Suppl. 1):11-25.
5
- Denis, A., C. Agouridas, J. M. Auger, Y. Benedetti, A. Bonnefoy, F. Bretin, J. F. Chantot, A. Dussarat, C. Fromentin, S. G. D'Ambrieres, S. Lachaud, P. Laurin, O. Le Martret, V. Loyau, N. Tessot, J. M. Pejac, and S. Perron. 1999. Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens. Bioorg. Med. Chem. Lett. 9:3075-3080.[CrossRef][Medline]
6
- Denis, A., F. Bretin, C. Fromentin, A. Bonnet, G. Piltan, A. Bonnefoy, and C. Agouridas. 2000. Synthesis and antibacterial activity of 2-halogeno, 2-methyl and 2,3 enol-ether ketolides. Bioorg. Med. Chem. Lett. 10:2019-2022.[CrossRef][Medline]
7
- Douthwaite, S., L. H. Hansen, and P. Mauvais. 2000. Macrolide-ketolide inhibition of MLS-resistant ribosomes is improved by alternative drug interaction with domain II of 23S rRNA. Mol. Microbiol. 36:183-193.[CrossRef][Medline]
8
- Goldman, R. C., and S. K. Kadam. 1989. Binding of novel macrolide structures to macrolides-lincosamides-streptogramins B-resistant ribosomes inhibits protein synthesis and bacterial growth. Antimicrob. Agents Chemother. 33:1058-1066.[Abstract/Free Full Text]
9
- Grillot-Courvalin, C., S. Goussard, F. Huetz, D. M. Ojcius, and P. Courvalin. 1998. Functional gene transfer from intracellular bacteria to mammalian cells. Nat. Biotechnol. 16:862-866.[CrossRef][Medline]
10
- Horinouchi, S., W. H. Byeon, and B. Weisblum. 1983. A complex attenuator regulates inducible resistance to macrolides, lincosamides, and streptogramin type B antibiotics in Streptococcus sanguis. J. Bacteriol. 154:1252-1262.[Abstract/Free Full Text]
11
- Leclercq, R., and P. Courvalin. 1991. Bacterial resistance to macrolide, lincosamide, and streptogramin antibiotics by target modification. Antimicrob. Agents Chemother. 35:1267-1272.[Free Full Text]
12
- Martin, B., G. Alloing, V. Méjean, and J. P. Claverys. 1987. Constitutive expression of erythromycin resistance mediated by ermAM determinant of plasmid pAMß1 results from deletion of 5' leader peptide sequences. Plasmid 18:250-253.[CrossRef][Medline]
13
- Roberts, M. C., J. Sutcliffe, P. Courvalin, L. B. Jensen, J. Rood, and H. Seppala. 1999. Nomenclature for macrolide and macrolide-lincosamide-streptogramin B resistance determinants. Antimicrob. Agents Chemother. 43:2823-2830.[Free Full Text]
14
- Rosato, A., H. Vicarini, A. Bonnefoy, J. F. Chantot, and R. Leclercq. 1998. A new ketolide, HMR 3004, active against streptococci inducibly resistant to erythromycin. Antimicrob. Agents Chemother. 42:1392-1396.[Abstract/Free Full Text]
15
- Rosato, A., H. Vicarini, and R. Leclercq. 1999. Inducible or constitutive expression of resistance in clinical isolates of streptococci and enterococci cross-resistant to erythromycin and lincomycin. J. Antimicrob. Chemother. 43:559-562.[Abstract/Free Full Text]
16
- Trieu-Cuot, P., C. Carlier, C. Poyart-Salmeron, and P. Courvalin. 1990. A pair of mobilizable shuttle vectors conferring resistance to spectinomycin for molecular cloning in Escherichia coli and in Gram-positive bacteria. Nucleic Acids Res. 18:4296.[Free Full Text]
17
- Weisblum, B. 1995. Erythromycin resistance by ribosome modification. Antimicrob. Agents Chemother. 39:577-585.[Medline]
18
- Weisblum, B. 1995. Insights into erythromycin action from studies of its activity as inducer of resistance. Antimicrob. Agents Chemother. 39:797-805.[Medline]
19
- Zhong, P., Z. Cao, R. Hammond, Y. Chen, J. Beyer, V. D. Shortridge, L. Y. Phan, S. Pratt, J. Capobianco, K. A. Reich, R. K. Flamm, Y. S. Or, and L. Katz. 1999. Induction of ribosome methylation in MLS-resistant Streptococcus pneumoniae by macrolides and ketolides. Microb. Drug Resist. 5:183-188.[Medline]
Antimicrobial Agents and Chemotherapy, July 2002, p. 2269-2272, Vol. 46, No. 7
0066-4804/02/$04.00+0 DOI: 10.1128/AAC.46.7.2269-2272.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Bailey, M., Chettiath, T., Mankin, A. S.
(2008). Induction of erm(C) Expression by Noninducing Antibiotics. Antimicrob. Agents Chemother.
52: 866-874
[Abstract]
[Full Text]
-
Depardieu, F., Podglajen, I., Leclercq, R., Collatz, E., Courvalin, P.
(2007). Modes and Modulations of Antibiotic Resistance Gene Expression. Clin. Microbiol. Rev.
20: 79-114
[Abstract]
[Full Text]